Zürich, Zurich, Switzerland The standard case for the fund is to invest in rounds with 4 partakers. Despite the Wille AG, startups are often financed by Paul Sevinu00e7, Gregory Gerhardt, WestTech Ventures. The meaningful sponsors for the fund in investment in the same round are Paul Sevinu00e7, Myke Naf, Gregory Gerhardt. In the next rounds fund is usually obtained by Paul Sevinu00e7, Myke Naf, investiere | Verve Capital Partners.
Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Nezasa. Among the most popular fund investment industries, there are B2B, Biotechnology.
The common things for fund are deals in the range of 5 - 10 millions dollars. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2013.
Related Funds
| Fund Name | Location |
| Conservice | Logan, United States, Utah |
| Duxx Investimentos | Brazil, São Paulo, Sao Paulo |
| Hil-Invent | - |
| Kubera Cross-Border Fund | Cayman Islands, Midland |
| MK Capital | Illinois, Northbrook, United States |
| NewPath Ventures | California, Santa Clara, United States |
| Pegasus Wings Group | - |
| Shanghai Fuli Investment Management | China, Jingan, Shanghai |
| Sichuan Hongda Investment | China, Gansu, Sichuan |
| Stargate Capital Investment Group | England, London, United Kingdom |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Araris Biotech | $24M | 04 Oct 2022 | Zurich, Zurich, Switzerland | ||
Visus Therapeutics | $36M | 09 Mar 2021 | Seattle, Washington, United States | ||
Raziel Health | $22M | 18 Dec 2019 | Florida, United States | ||
Labiotech.eu | 18 Sep 2017 | Berlin | |||
Nezasa | $806K | 25 Nov 2016 | Zurich, Zurich, Switzerland | ||
Nezasa | $763K | 02 Jun 2014 | Zurich, Switzerland | ||
Nezasa | $370K | 07 Aug 2013 | Zurich, Switzerland |
– Visus Therapeutics Inc. (the “Company”), a clinical-stage pharmaceutical company in pursuit of developing the world’s first presbyopia-correcting eye drop with the potential to last a minimum of eight hours, today announced the close of a $36 million Series A Preferred Stock financing.
– Johnson & Johnson Innovation – JJDC, Inc. (JJDC), RTW Investments, LP, and Wille AG participated in the round, with additional participation from the Company’s existing shareholders.
– Proceeds from the Series A financing will be used to advance the clinical development program for the company’s lead asset, BRIMOCHOL™, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Araris Biotech | $24M | 04 Oct 2022 | Zurich, Zurich, Switzerland | ||
Visus Therapeutics | $36M | 09 Mar 2021 | Seattle, Washington, United States | ||
Raziel Health | $22M | 18 Dec 2019 | Florida, United States | ||
Labiotech.eu | 18 Sep 2017 | Berlin | |||
Nezasa | $806K | 25 Nov 2016 | Zurich, Zurich, Switzerland | ||
Nezasa | $763K | 02 Jun 2014 | Zurich, Switzerland | ||
Nezasa | $370K | 07 Aug 2013 | Zurich, Switzerland |
